Shares of Simulations Plus (SLP) plummeted 9.61% in pre-market trading on Thursday, following the company's announcement of a significant cut to its full-year revenue outlook and a subsequent price target reduction by analysts.
The biosimulation and intelligence solutions provider revealed on Wednesday that it now expects fiscal 2025 revenue to be between $76 million and $80 million, a substantial decrease from its previous guidance of $90 million to $93 million. This revised outlook falls well short of the $90.3 million consensus estimate from analysts surveyed by FactSet. Additionally, Simulations Plus projected its fiscal Q3 revenue to be in the range of $19 million to $20 million, considerably below the $22.8 million analyst expectation.
Adding to the downward pressure, Stephens lowered its price target on Simulations Plus to $28 from $42, although it maintained an Overweight rating on the shares. This adjustment reflects the firm's reassessment of the company's near-term growth prospects in light of the reduced revenue guidance. The combination of disappointing financial projections and the analyst downgrade has evidently shaken investor confidence, leading to the sharp pre-market decline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.